Usana Health Sciences Stock News

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its full year and fiscal fourth quarter ended January 1, 2022. Key Financial & Operating Highlights Fiscal year 2021 net sales grew 5% to $1.186 billion. Reported fiscal year 2021 diluted EPS totaled $5.73. Fourth quarter net sales reached $267 million and diluted EPS were $1.03. Company provides initial 2022 net sales guidance of $1.125 to $1.225 billion and initial diluted EPS g

USANA Health Sciences (NYSE:USNA) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is $1.28 and the consensus

USANA Health (USNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The USANA HEALTH SCIENCES, INC PAC successfully filed their F3XN QUATERLY YEAR-END with the coverage period of 07/01/2021 to 12/31/2021 and a confirmation ID of FEC-1564159 *********CommitteeId: C00709295 | FilingId: 1564159 | FormType: F3XN | CoverageFrom: 07/01/2021 | CoverageThrough: 12/31/2021 | ReportType: QUATERLY YEAR-END*********

SALT LAKE CITY--(BUSINESS WIRE)--USANA Health Sciences, Inc. (NYSE:USNA) today announced that fourth quarter and FY 2021 results will be released after the close of market on Tuesday, February 8, 2022

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

USANA Health Sciences, Inc. (NYSE:USNA) COO Walter Noot sold 6,193 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, December 16th. The shares were sold at an average price of $102.25, for a total value of $633,234.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, []

Robeco Institutional Asset Management B.V. lowered its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 44.2% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 23,055 shares of the companys stock after selling 18,246 shares during the quarter. Robeco Institutional []

USANA Health Sciences, Inc. (NYSE:USNA) insider Daniel A. Macuga sold 368 shares of the firms stock in a transaction that occurred on Wednesday, December 8th. The shares were sold at an average price of $100.86, for a total transaction of $37,116.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which []

This is the 2nd hour in a row usna has seen its price head down. The post Usana Health Sciences Inc (USNA): Price Down $-0.92 (-0.91)% Over Past Day, Down $-0.58 (-0.57)% Over Past Hour appeared first on ETF Daily News .

Comerica Bank decreased its position in USANA Health Sciences, Inc. (NYSE:USNA) by 9.7% in the 2nd quarter, HoldingsChannel.com reports. The fund owned 10,822 shares of the companys stock after selling 1,163 shares during the quarter. Comerica Banks holdings in USANA Health Sciences were worth $1,023,000 as of its most recent SEC filing. Other hedge funds []

Price T Rowe Associates Inc. MD cut its stake in USANA Health Sciences, Inc. (NYSE:USNA) by 16.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,761 shares of the companys stock after selling 727 shares during the period. Price T Rowe []

Morgan Stanley trimmed its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 15.5% during the second quarter, Holdings Channel.com reports. The fund owned 79,489 shares of the companys stock after selling 14,594 shares during the quarter. Morgan Stanleys holdings in USANA Health Sciences were worth $8,143,000 as of its most recent SEC filing. []

Koshinski Asset Management Inc. bought a new position in shares of USANA Health Sciences, Inc. (NYSE:USNA) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 1,315 shares of the companys stock, valued at approximately $121,000. Several other large investors have also []

Metropolitan Life Insurance Co NY lifted its position in shares of USANA Health Sciences, Inc. (NYSE:USNA) by 112,266.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,371 shares of the company’s stock after purchasing an additional 3,368 shares during the period. Metropolitan Life Insurance […]